Last edition
News about "BAL Pharma"
BAL Pharma posts Rs 700.71 M revenue for Q1FY23
Revenue was impacted by macro and uncontrolled factors led by geopolitical concerns, external market turmoil and certain other unavoidable market factors
BAL Pharma | 16/08/2022 | By Sudeep Soparkar | 430
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members